AR126053A1 - Derivados de triazina - Google Patents
Derivados de triazinaInfo
- Publication number
- AR126053A1 AR126053A1 ARP220101456A ARP220101456A AR126053A1 AR 126053 A1 AR126053 A1 AR 126053A1 AR P220101456 A ARP220101456 A AR P220101456A AR P220101456 A ARP220101456 A AR P220101456A AR 126053 A1 AR126053 A1 AR 126053A1
- Authority
- AR
- Argentina
- Prior art keywords
- halo
- alkyl
- optionally substituted
- cycloalkyl
- haloalkyl
- Prior art date
Links
- 150000003918 triazines Chemical class 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- -1 -OH Chemical group 0.000 abstract 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 229910052763 palladium Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Compuestos de fórmula (1b) en donde R¹ es H, halo, alquilo, haloalquilo, haloalcoxi o nitrilo; R⁵ es H; o R¹ y R⁵, y los átomos a los que están unidos, forman o un anillo de heterociclo de 4 - 6 miembros que comprende un único heteroátomo de O opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente de halo o alquilo, o bien R¹ y R⁵, y los átomos a los que están unidos, forman un anillo de cicloalquilo de 3 - 6 miembros opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente de halo o alquilo; R² es H, halo, alquilo, haloalquilo, cicloalquilo o cicloalquilalquilo, en donde cicloalquilo o cicloalquilalquilo está opcionalmente sustituido con halo o haloalcoxi; R³ es H, alquilo, haloalquilo o cicloalquilo opcionalmente sustituido con halo; Z es -O-, -NH- o -NHCH₂-; R⁴ es un anillo de heterociclo opcionalmente sustituido con 1 a 2 sustituyentes seleccionados independientemente de halo, alquilo, haloalquilo, hidroxialquilo, -OH, oxo, -CO₂H o cicloalquilo opcionalmente sustituido con halo; o R⁴ es un cicloalquilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente de alquilo, halo, haloalquilo y -OH; y sales farmacéuticamente aceptable de estos. Reivindicación 24: Un proceso para preparar un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 22, que comprende la reacción de un compuesto de fórmula (IV) con un compuesto de fórmula (Va) en presencia de un catalizador de paladio y un ácido borónico o éster de pinacol borónico, en donde R¹, R², R³, R⁴, R⁵ y Z son como se definieron anteriormente, Esquema (1). Reivindicación 28: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 22 para el tratamiento o profilaxis de una enfermedad, trastorno o afección, en donde la enfermedad, trastorno o afección responde a la inhibición de NLRP3. Reivindicación 30: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 22 en el tratamiento o profilaxis de una enfermedad, trastorno o afección seleccionado de asma o EPOC.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21215875 | 2021-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126053A1 true AR126053A1 (es) | 2023-09-06 |
Family
ID=82115763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101456A AR126053A1 (es) | 2021-06-04 | 2022-06-02 | Derivados de triazina |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20240132471A1 (es) |
| EP (1) | EP4347571A1 (es) |
| JP (2) | JP7705963B2 (es) |
| KR (1) | KR20240019083A (es) |
| AR (1) | AR126053A1 (es) |
| AU (1) | AU2022287224A1 (es) |
| BR (1) | BR112023025318A2 (es) |
| CA (1) | CA3216026A1 (es) |
| CL (1) | CL2023003491A1 (es) |
| CO (1) | CO2023016212A2 (es) |
| CR (1) | CR20230566A (es) |
| IL (1) | IL307201A (es) |
| MX (1) | MX2023013998A (es) |
| PE (1) | PE20240928A1 (es) |
| TW (1) | TW202313577A (es) |
| WO (1) | WO2022253936A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US20240239758A1 (en) * | 2021-04-28 | 2024-07-18 | Astellas Pharma Inc. | Substituted triazine compound |
| AU2023205375A1 (en) * | 2022-01-07 | 2024-07-18 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and uses thereof |
| EP4558499A1 (en) * | 2022-07-21 | 2025-05-28 | F. Hoffmann-La Roche AG | Nlrp3 inhibitors |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| IL320499A (en) * | 2022-11-04 | 2025-06-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and use thereof |
| CR20250215A (es) * | 2022-12-07 | 2025-06-26 | Hoffmann La Roche | Compuestos novedosos como moduladores de la inhibición de nlrp3 |
| WO2024193541A1 (en) * | 2023-03-20 | 2024-09-26 | Insilico Medicine Ip Limited | Nlrp3 inflammasome inhibitors and uses thereof |
| WO2024193703A1 (zh) * | 2023-03-23 | 2024-09-26 | 成都赜灵生物医药科技有限公司 | 三嗪类化合物及其用途 |
| CN121039134A (zh) * | 2023-04-19 | 2025-11-28 | 豪夫迈·罗氏有限公司 | 5-[5-(2-羟基苯基)噁唑并[4,5-b]吡啶-2-基]哌啶-2-酮衍生物作为nlpr3抑制剂用于治疗炎性疾病 |
| WO2024218100A1 (en) * | 2023-04-19 | 2024-10-24 | F. Hoffmann-La Roche Ag | Oxazolo[4,5-b]pyrazine and oxazolo[4,5-b]pyridine derivatives as nlrp3 inhibitors for the treatment of e.g. inflammatory diseases |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| WO2025026882A1 (en) * | 2023-07-28 | 2025-02-06 | F. Hoffmann-La Roche Ag | Novel compounds |
| WO2025046419A1 (ko) * | 2023-08-25 | 2025-03-06 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025252772A1 (en) * | 2024-06-06 | 2025-12-11 | F. Hoffmann-La Roche Ag | Triazine derivatives |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018317798A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP |
| JP2021502364A (ja) | 2017-11-09 | 2021-01-28 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| CA3103943A1 (en) | 2018-07-25 | 2020-01-30 | Novartis Ag | Nlrp3 inflammasome inhibitors |
| KR20210124362A (ko) * | 2019-02-04 | 2021-10-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| CA3167023A1 (en) | 2020-01-22 | 2021-07-29 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as nlrp3 modulators |
| US20230107277A1 (en) | 2020-03-27 | 2023-04-06 | Astellas Pharma Inc. | Substituted pyridazine compound |
| CN116390914A (zh) | 2020-12-25 | 2023-07-04 | 上海拓界生物医药科技有限公司 | 一类含哒嗪的化合物及其医药用途 |
| CN116867769A (zh) | 2021-02-08 | 2023-10-10 | 南京明德新药研发有限公司 | 取代的哒嗪苯酚类衍生物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US20240239758A1 (en) | 2021-04-28 | 2024-07-18 | Astellas Pharma Inc. | Substituted triazine compound |
| US20240294542A1 (en) | 2021-06-05 | 2024-09-05 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| MX2024000234A (es) | 2021-07-02 | 2024-04-16 | Astrazeneca Ab | Inhibidores del inflamasoma nlrp3. |
| WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| AU2023205375A1 (en) | 2022-01-07 | 2024-07-18 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and uses thereof |
| CA3246681A1 (en) | 2022-03-25 | 2023-09-28 | Ventus Therapeutics U.S., Inc. | PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES |
| WO2024090469A1 (ja) | 2022-10-26 | 2024-05-02 | アステラス製薬株式会社 | 縮環ピリダジン誘導体 |
| CN115621720A (zh) * | 2022-10-27 | 2023-01-17 | 永道射频技术股份有限公司 | 一种应用于rfid读写器的全息超材料阵列天线 |
| IL320499A (en) | 2022-11-04 | 2025-06-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and use thereof |
| JP2026503239A (ja) | 2022-12-28 | 2026-01-28 | アストラゼネカ・アクチエボラーグ | Ｎｌｒｐ３インフラマソーム阻害剤 |
| CN120435466A (zh) | 2023-02-17 | 2025-08-05 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
-
2022
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko active Pending
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en not_active Ceased
- 2022-06-02 EP EP22731614.8A patent/EP4347571A1/en active Pending
- 2022-06-02 JP JP2023572751A patent/JP7705963B2/ja active Active
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 TW TW111120574A patent/TW202313577A/zh unknown
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/063,141 patent/US12421209B2/en active Active
- 2025-03-26 JP JP2025051003A patent/JP2025098157A/ja active Pending
- 2025-05-16 US US19/210,925 patent/US20250276958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3216026A1 (en) | 2022-12-08 |
| CR20230566A (es) | 2024-01-22 |
| US20250197370A1 (en) | 2025-06-19 |
| WO2022253936A1 (en) | 2022-12-08 |
| MX2023013998A (es) | 2023-12-11 |
| JP7705963B2 (ja) | 2025-07-10 |
| JP2025098157A (ja) | 2025-07-01 |
| CL2023003491A1 (es) | 2024-05-24 |
| US12421209B2 (en) | 2025-09-23 |
| US20250276958A1 (en) | 2025-09-04 |
| IL307201A (en) | 2023-11-01 |
| AU2022287224A1 (en) | 2023-09-21 |
| BR112023025318A2 (pt) | 2024-02-27 |
| US20240132471A1 (en) | 2024-04-25 |
| JP2024522494A (ja) | 2024-06-21 |
| EP4347571A1 (en) | 2024-04-10 |
| TW202313577A (zh) | 2023-04-01 |
| CO2023016212A2 (es) | 2023-12-11 |
| PE20240928A1 (es) | 2024-04-30 |
| KR20240019083A (ko) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126053A1 (es) | Derivados de triazina | |
| AR125818A1 (es) | Inhibidores de nlrp3 | |
| AR127705A1 (es) | Heterociclos inhibidores de nlrp3 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR127704A1 (es) | Derivados de piridazina inhibidores de nlrp3 | |
| ECSP10010405A (es) | Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico | |
| CU20160030A7 (es) | Compuestos éteres de arilo yútiles para tratar cancer de célula renal | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| AR063706A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. | |
| AR066153A1 (es) | Derivados de piperidina / piperazina | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR066191A1 (es) | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona | |
| AR066154A1 (es) | Derivados de piperidina / piperazina | |
| AR125026A1 (es) | Inhibidores del sarcómero cardíaco | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| AR081064A1 (es) | Compuestos de tetraciclina policiclica | |
| AR123435A1 (es) | Derivados de sulfamoil urea que contienen resto alquilo-oxacicloalquilo, y usos de los mismos | |
| AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas | |
| AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
| CU20100252A7 (es) | Derivados de dibenzotiazepina |